🔗 Share this article

Given that the United States continues making unprecedented adjustments to its vaccination recommendations, an unexpected name has emerged somewhat surprisingly: Tracy Beth Høeg, a Danish American physician and epidemiologist who first made her name by expressing skepticism about coronavirus vaccinations during the pandemic and has concentrated on alleged fatalities following COVID-19 immunization in her recent tenure at the US Food and Drug Administration (FDA).

Scheduled Changes to Childhood Immunization Schedule

Public health authorities planned to announce radical revisions to the childhood vaccination calendar in December, bringing the US with Denmark’s vaccine program, it is understood – a substantial departure that would place the US at odds with a large portion of the global community with insufficient data for public health gain. This reveal has been delayed until the next year.

In place of the top vaccines chief, Tracy Beth Høeg is scheduled to present at the gathering. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the office this year.

A New Direction at the Agency

This interim role might represent a strengthened alliance between the drug and vaccine divisions as Høeg and Dr. Prasad solidify control at the agency – and it points to a greater focus upon rolling back long-standing immunizations at the FDA.

Høeg has often pushed for halting certain childhood shot schedules in the US to become more similar to the Danish model, a nation with comprehensive healthcare and a population approximately the population of Wisconsin’s.

So far comments, she has persisted in emphasizing on vaccines – typically the responsibility of Prasad, chief of the FDA’s vaccine center – rather than medication approval.

Doubts Over Expertise

Dr. Høeg has little discernible experience in drug development, oversight or administrative roles, which has been typical for past directors of the biologics center. She has worked at the FDA as a top consultant to the commissioner and CBER since earlier this year.

“She doesn’t seem to have the necessary background” for overseeing the CDER, said Dr. Jonathan Howard. “She lacks experience running a clinical trial. She is not versed in running a major agency. She is not an expert in pharmaceutical oversight.”

Past directors of the center would “understand legal statutes and the research of medication creation”, noted Janet Woodcock. “Objectively, she doesn’t have the kind of background that former directors who ran CBER have had.”

CDER has an vast range of responsibilities at the agency, Woodcock pointed out.

“Everybody just pays attention on the novel medication approvals, but the off-patent medication office clears a multitude of off-brand pharmaceuticals. There is also a biosimilars program, OTC medication office and so forth, and each of these have to be supervised,” Dr. Woodcock noted. “The responsibility you neglect, that is the part that I always told people is going to cause problems.”

There is also, a significant management component to the position, which oversees over 5,000 staff members. “It’s a massive leadership role, if you execute it properly,” the former official concluded.

Official Statement and Disputed Policies

When asked about questions about Høeg’s qualifications and whether this appointment represents greater collaboration among regulatory chiefs on vaccines, a representative responded that the “inquiries rely on inaccurate assumptions”.

“Her resume matches the responsibilities of her role,” the representative explained, citing the months Dr. Høeg spent advising the agency head on “pharmaceutical safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Høeg takes over the agency head's controversial expedited review system, a disputed rapid medication authorization process that apparently concerned her preceding directors. “How are these drugs being chosen for this voucher program? Who takes the calls?” Dr. Howard questioned. “There’s a lot of secrecy happening at the agency right now.”

In general, he stated, “the agency seems to be moving towards more relaxed regulations of pharmaceuticals, except for shots.”

Documented Track Record on Vaccines

With vaccines, Høeg has a more established, if troubling, track record, critics observe. She released a research paper using unconfirmed volunteer-provided data to assess the rate of heart inflammation after Covid vaccination. She counseled the state of Florida top health official Dr. Joseph Ladapo, who was said to have altered data to indicate COVID-19 vaccines are riskier than they are.

Included in her “desired changes” for the current administration encompassed altering rules for novel immunizations and ending “unnecessary” immunizations, she stated after the election on a online show. At the FDA, Høeg has according to sources floated the idea of preventing adolescent males from getting COVID-19 vaccinations.

“She’s an thorough ideologue who begins with her beliefs and reverse-engineers to retrofit the data in a extremely disingenuous, fraudulent manner,” Howard argued.

Taking Control and a “Push for Payback”

Dr. Høeg became part of fellow skeptics, {like|